Solid state forms of a pharmaceutical
AssigneeHollis-Eden Pharmaceuticals, Inc.
InventorsSteven K. White, Igor Ivanisevic, Kyle Stephens, Mark Andres, Brenton Skylar Wolfe
Life of this patent
Estimating the term…
Loading patent…
AssigneeHollis-Eden Pharmaceuticals, Inc.
InventorsSteven K. White, Igor Ivanisevic, Kyle Stephens, Mark Andres, Brenton Skylar Wolfe
Estimating the term…
The invention provides and describes solid state 17α-ethynyl-androst-5-ene-3β,7β,17β-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17α-ethynyl-androst-5-ene-3β,7β,17β-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol and uses of such formulations in treating the described conditions.
Crystalline 17α-ethynylandrost-5-ene-3β,7β,17β-triol.
Amorphous 17α-ethynylandrost-5-ene-3β,7β,17β-triol substantially free of crystalline 17α-ethynylandrost-5-ene-3β,7β,17β-triol.
A method to make crystalline Form I 17α-ethynyl-androst-5-ene-3β,7β,17β-triol comprising the step of reducing in volume a solution of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol in methanol-water, methanol-tetrahydrofuran or acetone or removing methanol from a solution of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol in methanol-water by distillation concommitant with addition of water wherein the initial volume of the solution is substantially maintained or removing solvent from a solution of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol in ethanol by evaporation.
A method to treat an inflammation condition or a metabolic disorder in a subject comprising administering to the subject an effective amount of crystalline 17α-ethynylandrost-5-ene-3β,7β,17β-triol, optionally wherein the crystalline 17α-ethynylandrost-5-ene-3β,7β,17β-triol is Form I 17α-ethynylandrost-5-ene-3β,7β,17β-triol substantially free of amorphous 17α-ethynylandrost-5-ene-3β,7β,17β-triol or other crystalline forms of 17α-ethynylandrost-5-ene-3β,7β,17β-triol.
Dependencies are inferred from the claim text.